Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Harenberg, Job [VerfasserIn]   i
 Erdle, Sandra [VerfasserIn]   i
 Hetjens, Svetlana [VerfasserIn]   i
 Krämer, Roland [VerfasserIn]   i
Titel:Determination of rivaroxaban in human plasma samples
Verf.angabe:Job Harenberg, Sandra Erdle, Svetlana Marx, Roland Krämer
E-Jahr:2012
Jahr:17. Februar 2012
Umfang:7 S.
Fussnoten:Gesehen am 09.08.2018
Titel Quelle:Enthalten in: Seminars in thrombosis and hemostasis
Ort Quelle:New York, NY : Thieme, 1974
Jahr Quelle:2012
Band/Heft Quelle:38(2012), 2, Seite 178-184
ISSN Quelle:1098-9064
Abstract:<p>Rivaroxaban is one of the novel oral direct factor Xa inhibitors, which is effective in preventing thromboembolic complications at fixed doses (i.e., once daily), without the need for dose adjustment according to laboratory monitoring. Nearly 60% of rivaroxaban is cleared from circulation by glomerular filtration, 30% of which is excreted as active drug. Therefore, as renal elimination plays a pivotal role in the metabolism of this drug, impairment of renal function may be important during anticoagulation with rivaroxaban over long periods of time. The assessment of the anticoagulant effect/concentration of rivaroxaban may thus be useful in special patient populations such as in the elderly and eldest, during acute diseases with concurrent dehydration, before surgery, during bleeding or thrombotic episodes, or to verify adherence to therapy. Rivaroxaban prolongs prothrombin time in a dose-dependent, linear fashion. Activated partial thromboplastin time (APTT) is also prolonged, but in an exponential manner. Substantial differences in test results might be generated by different thromboplastin and APTT reagents. One-step prothrombin-induced clotting time assay is sensitive to low concentrations of rivaroxaban. Chromogenic substrate assays specific for factor Xa are also sensitive to rivaroxaban. Several initiatives are currently ongoing to standardize the various methods to determine rivaroxaban in human plasma samples, some of which will be summarized in this article along with the dose-dependent effects of rivaroxaban on relevant coagulation parameters. Therefore, although rivaroxaban prolongs all coagulation assays used to assess the anticoagulant effects of most anticoagulants, the most specific assay cannot be identified at present. Moreover, clinical trials are needed to determine the relationship of assay results with bleeding or thrombotic complications.</p>
DOI:doi:10.1055/s-0032-1301415
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.1055/s-0032-1301415
 Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1301415
 DOI: https://doi.org/10.1055/s-0032-1301415
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:157841816X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68293943   QR-Code
zum Seitenanfang